In this context, clinical reports have highlighted the potential of AP-2β as a therapeutic target for specific cancers such as lung adenocarcinoma [216], renal cell tumorigenesis [220], and breast [221] and endometrial cancers [217]. The gene discussed is TFAP2B; the disease is cancer.